Multiple Sclerosis and Related Disorders

Multiple Sclerosis and Related Disorders

Revising the neuromyelitis optica criteria 4:39
Revising the neuromyelitis optica criteria
Angela Vincent
Comorbidities in multiple sclerosis patients 3:33
Comorbidities in multiple sclerosis patients
Melinda Magyari
Initial high-efficacy disease-modifying therapy in multiple sclerosis 2:57
Initial high-efficacy disease-modifying therapy in multiple sclerosis
Melinda Magyari
Are MS patients at increased risk for developing cancer? 1:17
Are MS patients at increased risk for developing cancer?
Melinda Magyari
Neuromyelitis optica: new treatments and areas of development 7:45
Neuromyelitis optica: new treatments and areas of development
Brian Weinshenker
MS diagnosis: are the 2017 MS McDonald criteria too liberal? 6:41
MS diagnosis: are the 2017 MS McDonald criteria too liberal?
Brian Weinshenker
The problem with defining types of MS 3:10
The problem with defining types of MS
Gavin Giovannoni
The role of kynurenines in the pathogenesis of MS 3:25
The role of kynurenines in the pathogenesis of MS
Laszlo Vecsei
Understanding MS: PET imaging and microglial activity 3:19
Understanding MS: PET imaging and microglial activity
Laszlo Vecsei
Treating relapsing-remitting MS aggressively at disease presentation 2:38
Treating relapsing-remitting MS aggressively at disease presentation
Abhijit Chaudhuri
Is cognitive decline sufficient to define transition to secondary progressive MS? 2:48
Is cognitive decline sufficient to define transition to secondary progressive MS?
Laszlo Vecsei
The benefits of treatments with minimal scientific basis in MS 1:51
The benefits of treatments with minimal scientific basis in MS
Gavin Giovannoni
MS: challenges and the impact of a healthy lifestyle 2:16
MS: challenges and the impact of a healthy lifestyle
Abhijit Chaudhuri
Lessons to be learned from the laquinimod trial for MS 1:50
Lessons to be learned from the laquinimod trial for MS
Gavin Giovannoni
Treating MS: new therapies and COVID-19 3:23
Treating MS: new therapies and COVID-19
Abhijit Chaudhuri
Future avenues of MS treatment 2:04
Future avenues of MS treatment
Gavin Giovannoni
The content of VJNeurology is intended for healthcare professionals